This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We read with great interest the article by Sankar et al¹ and report a case series of secondary acute angle-closure glaucoma associated with topiramate (Topamax; Ortho-McNeil Pharmaceutical, Inc, Raritan, NJ) and submitted to the Food and Drug Administration's Center for Drug and Evaluation Research Adverse Events Reporting System between April 1999 and July 2001. The case series includes 19 patients, 2 of whom were described by Sankar et al. The patients were predominantly female (89%) with a mean age of 36.5 years (age range, 5-53 years). Indications included epilepsy (n = 5), depression (n = 5), neuropathic pain (n = 2), migraine (n = 2), bipolar disorder (n = 2), weight loss (n = 1), and unknown (n = 2). When doses were reported (53% of cases), they were within the recommended range. Time to symptom onset was reported in 15 cases and typically occurred soon after starting topiramate; the . . . [Full Text of this Article]